regulatory_compliance

Barnard, Vt. – September 13, 2026 -- MIB Agents began accepting letters of intent on September 9 for its 2027 OutSmarting Osteosarcoma research grant cycle, offering a combined $150,000 to fund translational studies on the pediatric bone cancer.

Two grants totaling $150,000 target established and emerging researchers

The 2027 cycle includes a $100,000 Hero Grant and a $50,000 Hope Young Investigator Grant. Since launching in 2017, the program has distributed more than $2.9 million across 37 investigators studying osteosarcoma, an aggressive primary bone cancer diagnosed in roughly 1,000 people annually in the United States, nearly half of them children, adolescents and young adults.

Azour, Israel – September 13, 2026 -- Ituran Location and Control Ltd. (Nasdaq: ITRN) has secured a contract worth over NIS 21 million (approximately $7 million) from entities under Israel's Ministry of Transport to supply a Software-as-a-Service traffic monitoring solution, with the first year guaranteed at NIS 5 million (approximately $1.7 million).

Ituran's Big Data platform tracks over one million vehicles across Israel

The contract runs for up to four years and relies on Ituran's proprietary Big Data platform, which analyzes anonymized data from more than one million vehicles -- roughly a quarter of all registered vehicles in Israel. The platform delivers macro-level traffic and driver behavior insights that Ministry-affiliated entities will use to shape national road policy and future infrastructure investment.

New York – September 13, 2026 -- Cyware is backing a Department of Energy-funded initiative led by the research arm of the National Rural Electric Cooperative Association (NRECA) to expand Operational Technology (OT) monitoring across nearly 900 electric cooperatives nationwide.

NRECA targets standardized threat data across rural utility networks

The project, run under NRECA's ICS-REC program, aims to standardize the collection, correlation and normalization of OT security data from participating rural cooperatives, enabling centralized analysis and faster threat detection across the grid.

Austin, Texas – September 13, 2026 -- Findhelp has become the first specialty exchange to register with the Maryland Health Care Commission (MHCC), enabling social care referral and reporting support for the state's Rural Health Transformation Program (RHTP).

Findhelp registers as Maryland's first specialty exchange under MHCC oversight

The registration allows Findhelp to help RHTP grant awardees manage social risk screening, referrals, data exchange, and reporting requirements. Health care providers and community-based organizations (CBOs) gain specialized technical capabilities intended to reduce barriers in care coordination for rural patients.

Chino, Calif. – September 13, 2026 -- Specialty Enzymes & Probiotics has published dual-track research showing its ingredient SlimSEBTM reduces post-meal blood sugar spikes by 16.90% in a controlled human clinical trial, providing formulators with clinically backed data for glucose-support supplements.

Clinical trial confirms 16.90% reduction in glucose AUC

In a double-blind, randomized, placebo-controlled crossover trial, subjects supplemented with SlimSEBTM showed a 16.90% reduction in Area Under the Curve (AUC), a standard measure of post-prandial glycemic response. The result demonstrates statistically significant improvement in blood sugar control following meals.

Vancouver – September 13, 2026 -- Century Lithium Corp. has submitted its Mine Plan of Operations and Nevada Reclamation Permit Application for the 100%-owned Angel Island lithium project in Esmeralda County, Nevada, starting the federal environmental review clock on one of the largest known sedimentary lithium deposits in the United States.

Company files 5,379-acre plan with U.S. Bureau of Land Management

The Plan of Operations was submitted September 3, 2026, to the BLM's Battle Mountain District, Tonopah Field Office, by wholly owned subsidiary Cypress Holdings (Nevada), Ltd. The document, prepared under 43 CFR Subpart 3809 and Nevada's NAC 519A regulations, will serve as the basis for the BLM's National Environmental Policy Act analysis. The Project Area covers 5,379 acres of BLM-administered public land, with approximately 2,364 acres of proposed disturbance.

Los Angeles – September 13, 2026 -- BLAZE has launched the BLAZE E-Commerce API, a headless commerce solution giving licensed cannabis dispensaries and multi-state operators full creative and technical control over their online storefronts while retaining compliance, inventory, and payment infrastructure required in regulated retail.

API grants developers full access to product, cart, order, and compliance data

The BLAZE E-Commerce API allows teams to build fully custom websites or in-store kiosks. It connects natively with BLAZE Retail POS, syncing inventory, pricing, and order data between a dispensary's physical and digital storefronts with minimal maintenance.

New York – September 13, 2026 -- Eddid Securities USA Inc., a FINRA-registered introducing broker-dealer, has secured FINRA-approved correspondent clearing arrangements with tZERO Group under FINRA Rule 4311, granting its clients regulated access to digital asset securities trading and custody.

Eddid USA gains access to tZERO Securities ATS for eligible digital asset securities

Eddid USA, the U.S. subsidiary of Hong Kong-based Eddid Financial, has entered agreements with tZERO's regulated broker-dealer subsidiaries covering trading, clearing, and custody. As a subscriber to the tZERO Securities ATS, operated by tZERO Securities, LLC, Eddid USA can now facilitate customer trading in eligible securities, including digital asset securities.

Toronto – September 13, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) will hold a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 10:30 a.m. EDT.

Cardiol schedules investor session at Lotte New York Palace Hotel

The session takes place in the Louis Room on the fourth floor of the venue. A live webcast will be available under the Events & Presentations section of the company's investor website.

Company advances Phase III trial for recurrent pericarditis treatment

Cardiol's lead candidate, CardiolRx, is being evaluated in the pivotal Phase III MAVERIC trial (NCT06708299) for recurrent pericarditis, following the completed Phase II MAvERIC-Pilot study (NCT05494788). The U.S. FDA has granted Orphan Drug Designation to CardiolRx for pericarditis, including the recurrent form of the disease.

Sydney – September 13, 2026 -- Kazia Therapeutics Limited (NASDAQ: KZIA) has dosed the first patient in Arm A of PNOC035, a Phase 2 platform study testing paxalisib combined with gemcitabine for recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT), an aggressive pediatric brain cancer with no approved therapies.

Preclinical data showed the combination nearly quadrupled median survival in an AT/RT model

In an orthotopic AT/RT preclinical model, the paxalisib-gemcitabine combination extended median survival from 22 to 82.5 days (p0.0001) and showed complementary anti-tumor activity across multiple AT/RT cell lines. These findings, previously presented at ISPNO, AACR and Neuro-Oncology meetings, formed the scientific basis for advancing into the multicenter PNOC035 trial.